CXCL10, upregulated in melanoma tissues (93), recruits CD8+ T cells and NK cells to tumors (55, 94), promoting anti-tumor immune responses (55, 57, 94), and serving as a predictive marker for immunotherapy outcomes (95). Here, CD8A is linked to neoplasm.